Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Breast 4Genitourinary 2Dermatologic 2Other neoplasm 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Melanoma 2Precancerous Conditions 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Lovastatin × Dermatologic × Clear all
NCT00462280 2014-10-31

Lovastatin in Treating Patients At High Risk of Melanoma

National Cancer Institute (NCI)

Phase 2 Completed
80 enrolled 35 charts
DermatologicOther neoplasm

Melanoma, Precancerous Conditions

NCT00963664 2009-09-09

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

NeoPlas Innovation

Phase 2 Withdrawn
250 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡